Robin Carhart-Harris

And that's the most advanced.

That's the closest to a breakthrough, I would say, with the regulators.

Yeah, they're talking about this rolling submission where not all of the data necessarily has to be submitted for a decision to come.

On the face of it, that sounds pretty optimistic.

But then I'm hearing mixed messages as well.

What were the implications and consequences of the FDA denial of the Lycos, MAPS, MDMA petition?

Yeah, I mean, it did cause this market correction.

So, you know, companies were, their valuation dropped quite dramatically.

And I think, you know, had that got through, that would have caused a general uplift, you know, rising tide for everyone in this space.

Were the reasons for it intelligible and justifiable?

Some of them, and some of them weren't.

Some of the data quality in terms of adverse events weren't fully reported, apparently.

I think Lycos was the commercial face of maps.

Mm-hmm.

And MAPS, Multidisciplinary Association of Psychedelic Studies, headed up by Rick Doblin.

And MAPS is, in a sense, an advocacy group for psychedelics generally.

Rick brings this incredible charisma, but it's not fundamentally, I think it's fair to say, an academic body, say, annexed to an obvious academic institution.

it's not really pure scientists sort of running things.

And I think that makes it a very easy target for this accusation of bias.

I mean, the bias is pretty overt, really.